Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients

NCT06583070 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06583070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06583070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 2, 2024
Completion date
March 31, 2027
Enrollment
300 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cancer, radiation therapy, recurrent renal cell cancer